THE DATA BEHIND OUR NON-ADDICTIVE PRODUCT CANDIDATES
Jeffrey Gudin, M.D., Virpax’s Chief Medical Officer, has presented various posters on Virpax’s scientific advancements and discoveries.
A poster entitled “Enkephalin as a Potential Analgesic and CNS Modulator“ appeared at PAINWeek 2021. It shows that nanoparticle encapsulation of enkephalin would lead to effective brain delivery and analgesia.
Another posters were presented at the 2019 Military Health System Research Symposium (MHSRS) on August 21, 2019: Sustained Non-Opioid Pain Management in Prolonged Field Care and Hospital Settings Using Probudur describes how the company’s proprietary liposomal bupivacaine gel demonstrated the ability to provide post-operative pain control for up to 96 hours.